Quetiapine monotherapy in bipolar II depression: Combined data from four large, randomized studies

International Journal of Bipolar Disorders

Volumn 1, Issue 1, 2013, Pages 1-12

  Young, Allan H ^a,m   Calabrese, Joseph R ^b   Gustafsson, Urban ^c   Berk, Michael ^d,j,k,l   McElroy, Susan L ^e,f   Thase, Michael E ^g   Suppes, Trisha ^h   Earley, Willie ⁱ  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d DEAKIN UNIVERSITY   (Australia)

^e LINDNER CENTER OF HOPE   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h VA PALO ALTO HEALTH CARE SYSTEM   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Bipolar II depression; Efficacy; Monotherapy; Quetiapine; Tolerability

Indexed keywords

CHLORAL HYDRATE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUETIAPINE; TRIACYLGLYCEROL; ZALEPLON; ZOLPIDEM TARTRATE; ZOPICLONE;

AKATHISIA; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BIPOLAR II DISORDER; COLD INJURY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPOMANIA; INSOMNIA; MANIA; MONOTHERAPY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; MUSCLE SPASM; NAUSEA; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESTLESSNESS; SEDATION; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

EID: 84896714887     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/2194-7511-1-10     Document Type: Article

References (58)

1. Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL, Grunze H, Kitchen CM, Post R. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006; 163(2):313-315.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 4th ed. Washington, DC: American Psychiatric Association; 2000.
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159 Suppl 4: 1-50.
4. Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, Merikangas KR. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010; 167(10):1194-1201.
5. Angst J, Gamma A, Azorin JM, Bowden CL, Perugi G, Vieta E, Young AH. Evidence-based efforts to re-define bipolar disorders. Bipolar Disord. 2011; 13 Suppl 1: 14.
6. Angst J, Gamma A, Bowden CL, Azorin JM, Perugi G, Vieta E, Young AH. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci. 2012; 262(1):3-11.
7. Bauer M, Beaulieu S, Dunner DL, Lafer B, Kupka R. Rapid cycling bipolar disorder-diagnostic concepts. Bipolar Disord. 2008; 10(1 Pt 2):153-162.
8. Benazzi F. Bipolar II, disorder: epidemiology, diagnosis and management. CNS Drugs. 2007; 21(9):727-40.
9. Berk M, Dodd S. Review: rapid cycling bipolar disorder associated with female gender and bipolar type II subgroup. Evid Based Ment Health. 2004; 7(3):91.
10. Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, Filia S, Filia K, Tahtalian S, Biffin F, Kelin K, Smith M, Montgomery W, Kulkarni J. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord. 2007; 103(1-3):181-6.
11. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005; 66(1):111-121.
12. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351-1360.
13. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10(2):323-333.
14. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010; 13(1):5-14.
15. Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011; 168(1):40-48.
16. Gao K, Tolliver BK, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady KT, Shim SS, Findling RL, Calabrese JR. Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008; 110(1-2):167-173.
17. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003; 17(2):149-173.
18. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009; 23(4):346-388.
19. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11(2):81-109.
20. Gustafsson U, Fajutrao L. Effect of quetiapine on functioning and quality of life in bipolar depression [abstract]. Eur Psychiatry. 2011; 26(Suppl 1):1935.
21. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-55.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
23. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006; 67(3):355-362.
24. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60(3):261-269.
25. Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: treatment of bipolar disorder. Postgraduate Med Special Report. 2004; 2004:1-120.
26. Kupka RW, Luckenbaugh DA, Post RM, Leverich GS, Nolen WA. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry. 2003; 64(12):1483-1494.
27. Kupka RW, Luckenbaugh DA, Post RM, Suppes T, Altshuler LL, Keck PE Jr, Frye MA, Denicoff KD, Grunze H, Leverich GS, McElroy SL, Walden J, Nolen WA. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry. 2005; 162 (7):1273-1280.
28. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck PE Jr, McElroy SL, Grunze H, Post RM. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007; 9(5):531-535.
29. Lee S, Tsang A, Kessler RC, Jin R, Sampson N, Andrade L, Karam EG, Mora ME, Merikangas K, Nakane Y, Popovici DG, Posada-Villa J, Sagar R, Wells JE, Zarkov Z, Petukhova M. Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry. 2010; 196(3):217-225.
30. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006; 163(2):232-239.
31. Li CT, Bai YM, Huang YL, Chen YS, Chen TJ, Cheng JY, Su TP. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012; 200(1):45-51.
32. Lydiard RB, Culpepper L, Schioler H, Gustafsson U, Paulsson B. Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 2009; 11(5):215-225.
33. MacQueen GM, Young LT. Bipolar II disorder: symptoms, course, and response to treatment. Psychiatr Serv. 2001; 52(3):358-61.
34. Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011; 129(1-3):317-320.
35. Maina G, Albert U, Bellodi L, Colombo C, Faravelli C, Monteleone P, Bogetto F, Cassano GB, Maj M. Health-related quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J Clin Psychiatry. 2007; 68(2):207-212.
36. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2):163-174.
37. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005; 15(5):573-585.
38. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007; 64(5):543-552.
39. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011; 68(3):241-251.
40. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-389.
41. Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, Weiss RD, Miyahara S, Thas ME, Sachs GS, Pollack MH. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006; 189:20-25.
42. Perugi G, Angst J, Azorin JM, Bowden C, Vieta E, Young AH. The bipolar-borderline personality disorders connection in major depressive patients. Acta Psychiatr Scand. 2013. doi:10.1111/acps.12083.
43. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, Comes M, Torrent C, Kapczinski F, Vieta E. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010; 13(8):984-988.
44. Seroquel Prescribing Information. Prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2012.
45. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007; 68(8):1237-1245.
46. Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry. 2002; 63(Suppl 10):29-33.
47. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008; 9(3):198-211.
48. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011; 72(3):356-366.
49. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006; 26(6):600-609.
50. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1):13-20.
51. Valtonen H, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa ET. Suicidal ideation and attempts in bipolar I and II disorders. J Clin Psychiatry. 2005; 66(11):1456-1462.
52. Vazquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. Pharmacopsychiatry. 2011; 44(1):21-26.
53. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007; 9(4):413-425.
54. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72(11):1452-1464.
55. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15(1):1-44.
56. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133:429-435.
57. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71(2):150-162.
58. Young AH, McElroy SL, Olausson B, Paulsson B. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2012. doi:10.3109/15622975.2012.665177.